Switch theme
Sign up to access all valuation multiples
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.
1980
5.5K+
LTM Revenue $1.3B
LTM EBITDA $319M
$6.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Stevanato Group has a last 12-month revenue of $1.3B and a last 12-month EBITDA of $319M.
In the most recent fiscal year, Stevanato Group achieved revenue of $1.1B and an EBITDA of $248M.
Stevanato Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Stevanato Group valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.1B | $1.1B | XXX | XXX | XXX |
| Gross Profit | $320M | $340M | XXX | XXX | XXX |
| Gross Margin | 29% | 31% | XXX | XXX | XXX |
| EBITDA | $272M | $248M | XXX | XXX | XXX |
| EBITDA Margin | 25% | 22% | XXX | XXX | XXX |
| Net Profit | $143M | $146M | XXX | XXX | XXX |
| Net Margin | 13% | 13% | XXX | XXX | XXX |
| Net Debt | n/a | $308M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Stevanato Group's stock price is $22.
Stevanato Group has current market cap of $6.1B, and EV of $6.5B.
See Stevanato Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.5B | $6.1B | XXX | XXX | XXX | XXX | $0.54 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Stevanato Group has market cap of $6.1B and EV of $6.5B.
Stevanato Group's trades at 5.2x LTM EV/Revenue multiple, and 21.8x LTM EBITDA.
Analysts estimate Stevanato Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Stevanato Group and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $6.5B | XXX | XXX | XXX |
| EV/Revenue | 5.9x | XXX | XXX | XXX |
| EV/EBITDA | 26.1x | XXX | XXX | XXX |
| P/E | 51.8x | XXX | XXX | XXX |
| P/E/Growth | 1.7x | XXX | XXX | XXX |
| EV/FCF | -41.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpStevanato Group's NTM/LTM revenue growth is 11%
Stevanato Group's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $26K for the same period.
Over next 12 months, Stevanato Group's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Stevanato Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Stevanato Group and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -9% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 34% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $26K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 13% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Schott Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Fresenius Medical Care | XXX | XXX | XXX | XXX | XXX | XXX |
| Fresenius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Stevanato Group acquired XXX companies to date.
Last acquisition by Stevanato Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Stevanato Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Stevanato Group founded? | Stevanato Group was founded in 1980. |
| Where is Stevanato Group headquartered? | Stevanato Group is headquartered in United States of America. |
| How many employees does Stevanato Group have? | As of today, Stevanato Group has 5.5K+ employees. |
| Who is the CEO of Stevanato Group? | Stevanato Group's CEO is Mr. Franco Stevanato. |
| Is Stevanato Group publicy listed? | Yes, Stevanato Group is a public company listed on NYS. |
| What is the stock symbol of Stevanato Group? | Stevanato Group trades under STVN ticker. |
| When did Stevanato Group go public? | Stevanato Group went public in 2021. |
| Who are competitors of Stevanato Group? | Similar companies to Stevanato Group include e.g. Ansell, Polymed, Schott Pharma, Fresenius Medical Care. |
| What is the current market cap of Stevanato Group? | Stevanato Group's current market cap is $6.1B |
| What is the current revenue of Stevanato Group? | Stevanato Group's last 12-month revenue is $1.3B. |
| What is the current EBITDA of Stevanato Group? | Stevanato Group's last 12-month EBITDA is $319M. |
| What is the current EV/Revenue multiple of Stevanato Group? | Current revenue multiple of Stevanato Group is 5.2x. |
| What is the current EV/EBITDA multiple of Stevanato Group? | Current EBITDA multiple of Stevanato Group is 21.8x. |
| What is the current revenue growth of Stevanato Group? | Stevanato Group revenue growth between 2023 and 2024 was 2%. |
| Is Stevanato Group profitable? | Yes, Stevanato Group is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
